Skip to Content

VITAL Grant

The VITAL grant consists of an umbrella trial called “Vanguard.” This clinical trial targets current or former smokers with a diagnosis of stage I, II or IIIa non-small cell lung cancer who have undergone complete surgical resection of the primary tumor within the past 12 months, or stage I or II head and neck squamous cell cancer who have been treated with surgery or radiation therapy within the past 12 months.

Patients who meet all the eligibility criteria will be enrolled into the Vanguard trial and followed for a total of 48 months. Vanguard is not a treatment trial. Patients will be evaluated with CT scan, bronchoscopy, and blood tests at specific time periods. The main objective of this study is to determine how long high-risk patients remain free of disease before developing a recurrence or a second tumor of the lung.

Patients enrolled in the Vanguard trial may be eligible for one of two additional clinical trials:

  • Patients with stage I, II, or IIIa non-small cell lung cancer who have undergone a complete surgical resection of the primary tumor within the past 12 months and have no evidence of disease, or
  • Patients with stage I or II head and neck squamous cell cancer who have undergone surgery or radiation therapy within the past 12 months and have no evidence of disease may be treated with celecoxib or erlotinib for one year.

The main objective of these two studies is to determine the effect of the drug in patients with previously treated disease.

Related Care Centers

Related Diseases


© 2014 The University of Texas MD Anderson Cancer Center